Sarpogrelate

DB12163InvestigationalSmall molecule

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2A
Curator reviewed
Formula / weight: C₂₄H₃₁NO₆ · 429.513 g/mol (avg)
Code names: MCI-9042

Resolves to

Compound

UNII19P708E787CAS125926-17-2ChEMBLCHEMBL52939ChEBI135697PubChem5160

Structure

InChIKeyFFYNAVGJSYHHFO-UHFFFAOYSA-NSMILESCOC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

Targets

P28223HTR2AP28335HTR2C

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,031Drug interactionsStructured to mechanism, not free text

18Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sarpogrelate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account